ST3GAL4 and acute myeloid leukemia: Thus, to prevent or overcome the resistance to treatment of high sLex-expressing AML subtypes such as M5, FUT7/ST3GAL4 as well as their biosynthetic products may be promising targets for the development of novel glycan-targeting therapies.